A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled, Basket Study With an Open-label Extension to Investigate the Efficacy, Safety, and Tolerability of Remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in Adults Inadequately Controlled by H1-antihistamines
概览
- 阶段
- 3 期
- 干预措施
- Remibrutinib
- 疾病 / 适应症
- Chronic Inducible Urticaria
- 发起方
- Novartis Pharmaceuticals
- 入组人数
- 362
- 试验地点
- 158
- 主要终点
- Proportion of participants with complete response in critical temperature threshold; cold urticaria
- 状态
- 进行中（未招募）
- 最后更新
- 2个月前
概览
简要总结
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).
The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs).
The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data on remibrutinib in participants after having completed the Core period
详细描述
This study consists of a core and extension periods. The Core period (6 arms) has a total duration of up to 60 weeks including a double-blind placebo-controlled treatment period until Week 24 followed by open-label treatment with remibrutinib up to Week 52. The primary endpoint for all CINDU subtypes is assessed at Week 12. The Core period consists of: * Screening period (up to 4 weeks): During the screening period, participants who have provided informed consent will be assessed for study eligibility. * Double-blind, placebo-controlled treatment period (24 weeks): 24 weeks of double-blind treatment with remibrutinib or placebo. * Open-label treatment period (28 weeks): 28 weeks of open-label treatment with remibrutinib. * Follow-up period: 4 weeks of treatment free follow-up. The open-label extension period consists of observation and treatment period. At the end of the core period of the study, if participants continue to experience symptoms, they will transition to the treatment period in OLE. If they do not experience symtpoms they will transition to the observation period in the OLE. The duration of the Open-label Extension period will be approximately 3 years where participants can switch from observation to treatment depending on if they start developing symptoms. Only those participants participating in the Open-label Extension Treatment period will receive remibrutinib. The participants in the Open-label Extension Observation period will not receive remibrutinib
研究者
入排标准
入选标准
- •for core period:
- •Male and female participants ≥18 years of age at the time of signing of the ICFs
- •Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, cold urticaria or cholinergic urticaria for ≥ 4 months (defined as onset of CINDU with supporting documentation (e.g medical record, clinical history, photographs)) and inadequate control with H1-AH at local label approved doses at the time of randomization
- •The following response to the provocation test for each subtype is required at the randomization visit :
- •Symptomatic Dermographism: A Total Fric Score of ≥3 using the FricTest® 4.0 and a numerical rating scale score of ≥5 for itch after the provocation test.
- •Cold Urticaria: A Critical Threshold Temperature of ≥15°C using the TempTest® 4.0 and a numerical rating scale score of ≥5 for itch after the provocation test.
- •Cholinergic Urticaria: A physician global assessment of severity of hives ≥ 2 using the Pulse-controlled ergometry test and a numerical rating scale score of ≥5 for itch after the provocation test.
- •Cold Urticaria: Positive ice-cube test resulting in hives at the provocation site for participants at Screening.
- •Cholinergic urticaria: Participants must show sweating in performing the pulse-controlled ergometry test on day of randomization. Participants with anhidrosis must not be included.
- •Inclusion criteria for the OLE:
排除标准
- •for core period:
- •1\. Previous use of remibrutinib or other BTK inhibitors.
- •Participants who have concomitant CSU at screening. Participants with resolved CSU at the time of screening can be included in the study.
- •Participants who have a familial form (e.g familial cold autoinflammatory syndrome, familial cold urticaria) of the target CINDU that is being considered for the participant's inclusion in this study.
- •Participants having a more defined other form of inducible urticaria than the target CINDU that is being considered for the participant's inclusion in this study.
- •Diseases, other than chronic inducible urticaria, with urticaria or angioedema symptoms including but not limited to urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema
- •Any other skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.) or skin diseases associated with only wheals and no itch e.g asymptomatic dermographism
- •There are no exclusion criteria for OLE
研究组 & 干预措施
Remibrutinib, symptomatic dermographism group
Remibrutinib oral twice daily in participants with symptomatic dermographism
干预措施: Remibrutinib
Placebo, symptomatic dermographism group
Placebo oral twice daily, symptomatic dermographism
干预措施: Placebo
Remibrutinib, cold urticaria group
Remibrutinib oral twice daily, cold urticaria
干预措施: Remibrutinib
Placebo, cold urticaria group
Placebo oral twice daily, cold urticaria
干预措施: Placebo
Remibrutinib, cholinergic urticaria group
Remibrutinib oral twice daily, cholinergic urticaria
干预措施: Remibrutinib
Placebo, cholinergic urticaria
Placebo oral twice daily, cholinergic urticaria
干预措施: Placebo
结局指标
主要结局
Proportion of participants with complete response in critical temperature threshold; cold urticaria
时间窗: Week 12
The Temptest is used to induce itch and hives in participants with cold urticaria. Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.
Proportion of participants with itch numerical rating scale =0; cholinergic urticaria
时间窗: Week 12
Itch numerical rating scale, a scale from 0 to 10 Patients are asked to rate itching severity based on the worst level of itching in the past 24 h using an 11-point scale from 0 ("no itch") to 10 ("worst itch imaginable")
Proportion of participants with complete response in Total Fric Score; symptomatic dermographism
时间窗: Week 12
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
次要结局
- Change from baseline in itch NRS in participants with symptomatic dermographism(Week 2)
- Change from baseline in itch NRS in participants with cold urticaria(Week 2)
- Proportion of participants with cholinergic urticaria with PGA=0(Week 2)
- Change from baseline in criticial temperature threshold following Temptest; cold urticaria(Week 12)
- Change from baseline in itch numerical rating scale; cholinergic urticaria(Week 12)
- Change from baseline in Critical Temperature Threshold in participants with cold urticaria(Week 2)
- Change from baseline in itch NRS in participants with cholinergic urticaria(Week 2)
- Change from baseline in Total Fric score; symptomatic dermographism(Week 12)
- proportion of participants with Physician Global Assessment (PGA) severity of hives =0; cholinergic urticaria(Week 12)
- Proportion of participants with complete response in TFS; symptomatic dermographism(Week 24)
- Proportion of participants with complete response in itch numerical rating scale; cholinergic urticaria(Week 24)
- Change from baseline in itch numerical rating scale in participants with symptomatic dermographism(Week 12)
- Change from baseline in itch numerical rating scale in participants with cold urticaria(Week 12)
- Proportion of participants with complete response in Total Fric score; symptomatic dermographism(Week 2)
- Proportion of participants with complete response in Critical Temperature Threshold; cold urticaria(Week 2)
- Proportion of participants with itch NRS=0; cholinergic urticaria(Week 2)
- Change from baseline in TFS in participants with symptomatic dermographism(Week 2)
- Proportion of participants with complete response in Critical Temperature threshold; cold urticaria(Week 24)
- Change from baseline in weekly most bothersome symptom NRS score on the USDD(Week 12)
- Occurrence of treatment emergent adverse events and serious adverse events during the study(Week 52)
- Proportion of participants with DLQI=0-1(Week 12)